Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients ; volume:9 ; number:1 ; day:19 ; month:2 ; year:2019 ; pages:1-8 ; date:12.2019
Scientific reports ; 9, Heft 1 (19.2.2019), 1-8, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Ghasemi, Faramarz
Abdi, Alireza
Salari, Nader
Tohidi, Mohammad Reza
Faraji, Aazam
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-38193-z
- URN
-
urn:nbn:de:101:1-2019031523070409788273
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ghasemi, Faramarz
- Abdi, Alireza
- Salari, Nader
- Tohidi, Mohammad Reza
- Faraji, Aazam
- SpringerLink (Online service)
Ähnliche Objekte (12)
Erythropoietin-producing tubercle granuloma in a hemodialysis patient
Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial)
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo
Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients
Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient
Intravenous iron and erythropoietin therapy for postoperative anemia among orthopedic surgery patients
Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients
Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data
Erythropoietin-producing tubercle granuloma in a hemodialysis patient
Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial)
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo
Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients
Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient
Intravenous iron and erythropoietin therapy for postoperative anemia among orthopedic surgery patients
Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients
Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data
Erythropoietin-producing tubercle granuloma in a hemodialysis patient
Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial)
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo
Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients
Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient
Intravenous iron and erythropoietin therapy for postoperative anemia among orthopedic surgery patients
Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients
Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients